Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "Hiberix" (45)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
(Codice) 44 products
WHO-DDD
L
IP
V/S
Infanrix DTPa-IPV
20.20
38.40
10 %
8 Active Agents
GlaxoSmithKline AG
B / SL
FB
G
L
IP
V/S
Engerix-B 20
23.66
42.15
10 %
Injection suspension: Hepatitidis b viri Antigenum Adnr 20 µg/ml
GlaxoSmithKline AG
B / SL
FB
G
IP
CI
Casgevy 4-13 x 10e6
cells/ml
PR
PR
k.A.
Vertex
Pharmaceuticals (CH)
GmbH
A
FB
G
IP
CI
Ebvallo
PR
PR
k.A.
Pierre Fabre Pharma SA
A
FB
G
IP
CI
BILAXIN Ophta 6 mg / ml
5 ml
PR
PR
k.A.
Eye drops: Bilastinum 6 mg/ml
A. Menarini GmbH
D
FB
G
IP
V/S
Engerix-B 20
10
PR
PR
k.A.
Injection suspension: Hepatitidis b viri Antigenum Adnr 20 µg/ml
GlaxoSmithKline AG
B
FB
G
IP
CI
Imodium
‐
I
-
T
20 Capsule(s)
3.87
6.85
20 %
Capsules: Loperamidi Hydrochloridum 2 mg
JNTL Consumer Health II
(Switzerland) GmbH
D / SL / SO
FB
G
IP
CI
Imodium
-
T
60 Capsule(s)
9.40
26.60
20 %
Capsules: Loperamidi Hydrochloridum 2 mg
JNTL Consumer Health II
(Switzerland) GmbH
B / SL / SO
FB
G
IP
CI
Incruse Ellipta
30 unidose(s)
34.64
54.10
10 %
Inhalation Powder: Umeclidinium 62.5 µg
GlaxoSmithKline AG
B / SL
FB
G
IP
CI
Incruse Ellipta
3 x 30 unidose(s)
103.00
128.45
10 %
Inhalation Powder: Umeclidinium 62.5 µg
GlaxoSmithKline AG
B / SL
FB
G
L
IP
V/S
Hiberix
Set(s)
16.16
34.00
10 %
Haemophilus Influenzae b Polysaccharida (Prp) 10 mcg
GlaxoSmithKline AG
B / SL
FB
G
L
IP
CI
Microlax
4 x 5 ml
4.15
7.65
10 %
Enema: 3 Active Agents
JNTL Consumer Health II
(Switzerland) GmbH
D / SL
FB
G
L
IP
CI
Microlax
12 x 5 ml
12.45
23.00
10 %
Enema: 3 Active Agents
JNTL Consumer Health II
(Switzerland) GmbH
D / SL / LPPV
FB
G
L
IP
CI
Microlax
50 x 5 ml
51.88
95.80
10 %
Enema: 3 Active Agents
JNTL Consumer Health II
(Switzerland) GmbH
D / SL / LPPV
FB
G
L
IP
Vegzelma 100 mg/4 ml
257.57
296.55
10 %
Concentrate for infusion: Bevacizumabum 100mg / 4ml
iQone Healthcare
Switzerland SA
A / SL
FB
G
L
IP
Vegzelma 400 mg/16 ml
962.84
1063.55
10 %
Concentrate for infusion: Bevacizumabum 400mg / 16ml
iQone Healthcare
Switzerland SA
A / SL
FB
G
L
IP
CI
D3 VitaCaps 24,000 IU
(600 μg)
6
7.65
17.55
10 %
Soft capsules: Cholecalciferolum 600 µg
Pierre Fabre Pharma SA
B / SL
FB
G
L
IP
CI
Vitamin D3 Sandoz eco
1000 I.E.
30
1.68
3.10
10 %
Soft capsules: Cholecalciferolum 1000 UI
Sandoz
Pharmaceuticals AG
● 
D / SL
FB
G
L
IP
CI
Vitamin D3 Sandoz eco
1000 I.E.
90
5.04
9.30
10 %
Soft capsules: Cholecalciferolum 1000 UI
Sandoz
Pharmaceuticals AG
● 
D / SL
FB
G
L
IP
CI
Vitamin D3 Sandoz eco
3200 I.E.
30
5.38
15.10
10 %
Soft capsules: Cholecalciferolum 3200 UI
Sandoz
Pharmaceuticals AG
● 
B / SL
FB
G
L
IP
CI
Vitamin D3 Sandoz eco
3200 I.E.
90
16.13
33.95
10 %
Soft capsules: Cholecalciferolum 3200 UI
Sandoz
Pharmaceuticals AG
● 
B / SL
FB
G
L
IP
CI
Vitamin D3 Sandoz eco
25000 I.E.
4
5.60
15.30
10 %
Soft capsules: Cholecalciferolum 25000 UI
Sandoz
Pharmaceuticals AG
B / SL
FB
G
IP
CI
Arnuity Ellipta 90 mcg
30 unidose(s)
15.60
33.40
10 %
Einzeldosiertes Pulver zur Inhalation: Fluticasoni Furoas 90 µg
GlaxoSmithKline AG
B / SL
FB
G
IP
CI
Arnuity Ellipta 90 mcg
3 x 30
46.80
67.30
10 %
Einzeldosiertes Pulver zur Inhalation: Fluticasoni Furoas 90 µg
GlaxoSmithKline AG
B / SL
FB
G
IP
CI
Arnuity Ellipta 182 mcg
30 unidose(s)
25.58
44.25
10 %
Einzeldosiertes Pulver zur Inhalation: Fluticasoni Furoas 182 µg
GlaxoSmithKline AG
B / SL
FB
G
IP
CI
Arnuity Ellipta 182 mcg
3 x 30
76.74
99.90
10 %
Einzeldosiertes Pulver zur Inhalation: Fluticasoni Furoas 182 µg
GlaxoSmithKline AG
B / SL
FB
G
L
IP
PP
Herceptin subkutan
600mg/5ml
1484.04
1630.40
10 %
Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
IP
Ogivri 150 mg
456.84
513.25
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg
Medius AG
A / SL
FB
G
L
IP
V/S
Menveo
Kombipackung(en)
31.69
50.90
10 %
Pulver und Lösung (Durchstechflaschen): Oligosaccharida Neisseriae Meningitidis A 10 µg
Pulver und Lösung (Durchstechflaschen): 3 Active Agents
GlaxoSmithKline AG
B / SL
FB
G
L
IP
V/S
Menveo
5 Kombipackung(en)
158.45
37.75
10 %
Pulver und Lösung (Durchstechflaschen): Oligosaccharida Neisseriae Meningitidis A 10 µg
Pulver und Lösung (Durchstechflaschen): 3 Active Agents
GlaxoSmithKline AG
B / SL
FB
G
IP
CI
Imodium lingual akut
10
PR
PR
k.A.
Melting tablets: Loperamidi Hydrochloridum 2 mg
JNTL Consumer Health II
(Switzerland) GmbH
D
FB
G
IP
CI
Imodium lingual akut
12
PR
PR
k.A.
Melting tablets: Loperamidi Hydrochloridum 2 mg
JNTL Consumer Health II
(Switzerland) GmbH
D
FB
G
IP
CI
Nicorette Microtab
Original-Aroma
100 Tablet(s)
PR
PR
k.A.
Sublingual tablets: Nicotinum 2 mg
JNTL Consumer Health II
(Switzerland) GmbH
D / LPPV
FB
G
IP
CI
D3 VitaCaps 24,000 IU
(600 μg)
4
PR
PR
k.A.
Soft capsules: Cholecalciferolum 600 µg
Pierre Fabre Pharma SA
B
FB
G
IP
CI
D3 VitaCaps 24,000 IU
(600 μg)
8
PR
PR
k.A.
Soft capsules: Cholecalciferolum 600 µg
Pierre Fabre Pharma SA
B
FB
G
IP
CI
D3 VitaCaps 24,000 IU
(600 μg)
12
PR
PR
k.A.
Soft capsules: Cholecalciferolum 600 µg
Pierre Fabre Pharma SA
B
FB
G
IP
CI
Vitamin D3 Sandoz eco
25000 I.E.
8
PR
PR
k.A.
Soft capsules: Cholecalciferolum 25000 UI
Sandoz
Pharmaceuticals AG
B
FB
G
IP
CI
Vitamin D3 Sandoz eco
25000 I.E.
12
PR
PR
k.A.
Soft capsules: Cholecalciferolum 25000 UI
Sandoz
Pharmaceuticals AG
B
FB
G
IP
Arnuity Ellipta 46 mcg
30
PR
PR
k.A.
Einzeldosiertes Pulver zur Inhalation: Fluticasoni Furoas 46 µg
GlaxoSmithKline AG
B
FB
G
IP
CI
Regaine 2 %
60 ml
PR
PR
k.A.
Solution: Minoxidilum 20 mg/ml
JNTL Consumer Health II
(Switzerland) GmbH
D / LPPV
FB
G
IP
CI
Regaine 2 %
3 x 60 ml
PR
PR
k.A.
Solution: Minoxidilum 20 mg/ml
JNTL Consumer Health II
(Switzerland) GmbH
D / LPPV
FB
G
IP
CI
Regaine 5 %
60 ml
PR
PR
k.A.
Solution: Minoxidilum 50 mg/ml
JNTL Consumer Health II
(Switzerland) GmbH
D / LPPV
FB
G
IP
CI
Regaine 5 %
3 x 60 ml
PR
PR
k.A.
Solution: Minoxidilum 50 mg/ml
JNTL Consumer Health II
(Switzerland) GmbH
D / LPPV
FB
G
IP
Mylotarg 5 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg
Pfizer AG
A
FB
G
Haemophilus Influenzae B, Purified Antigen Conjugated (J07AG01) 1 products
WHO-DDD
DrugBank.ca
L
IP
V/S
Hiberix
Set(s)
16.16
34.00
10 %
Haemophilus Influenzae b Polysaccharida (Prp) 10 mcg
GlaxoSmithKline AG
B / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home